Compare KRMD & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | IVA |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.5M | 1.1B |
| IPO Year | 2019 | 2020 |
| Metric | KRMD | IVA |
|---|---|---|
| Price | $3.21 | $4.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $6.50 | ★ $16.20 |
| AVG Volume (30 Days) | 257.3K | ★ 681.1K |
| Earning Date | 05-06-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,127,366.00 | N/A |
| Revenue This Year | $20.32 | N/A |
| Revenue Next Year | $17.37 | $751.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $3.21 | $3.35 |
| 52 Week High | $6.61 | $7.98 |
| Indicator | KRMD | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 30.00 | 55.78 |
| Support Level | $3.21 | $4.11 |
| Resistance Level | $4.27 | $4.94 |
| Average True Range (ATR) | 0.19 | 0.18 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 3.48 | 68.75 |
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.